Back to Journals » Breast Cancer: Targets and Therapy
Breast Cancer: Targets and Therapy
- View all (732)
- Volume 18, 2026 (81)
- Volume 17, 2025 (104)
- Volume 16, 2024 (76)
- Volume 15, 2023 (79)
- Volume 14, 2022 (41)
- Volume 13, 2021 (58)
- Volume 12, 2020 (27)
- Volume 11, 2019 (32)
- Volume 10, 2018 (24)
- Volume 9, 2017 (64)
- Volume 8, 2016 (26)
- Volume 7, 2015 (36)
- Volume 6, 2014 (20)
- Volume 5, 2013 (13)
- Volume 4, 2012 (22)
- Volume 3, 2011 (16)
- Volume 2, 2010 (9)
- Volume 1, 2009 (4)
Journal Articles:
- Nanoparticles for Breast Cancer Treatment (1)
- Antibody-Drug Conjugates for Breast Cancer Treatment (1)
- Targeting Triple-Negative Breast Cancers: Modern Advancements and Future Directions (4)
- Aging and microenvironment in breast cancer (5)
Dual Receptor Targeting Ensures Uptake and Anticancer Efficacy of Low-Density Lipoprotein-Docosahexaenoic Acid Nanoparticles Across Breast Cancer Cell Subtypes
Bower J, Anwar A, Chaudhary J, Chen Z, Schumacher M, Debose-Boyd R, Corbin IR
Breast Cancer: Targets and Therapy 2025, 17:1159-1182
Published Date: 6 December 2025
Efficacy of Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Metastatic Breast Cancer: A Real-World Retrospective Cohort Study in China
Yan Y, Jin Y, Lin M, Zeng C, Guo Q, Zhou T, Li DD, Zhang J
Breast Cancer: Targets and Therapy 2025, 17:863-873
Published Date: 25 September 2025
Role of AURKB Inhibition in Reducing Proliferation and Enhancing Effects of Radiotherapy in Triple-Negative Breast Cancer
Pellizzari S, Athwal H, Bonvissuto AC, Parsyan A
Breast Cancer: Targets and Therapy 2024, 16:341-346
Published Date: 9 July 2024
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial
Chen Y, Li WX, Wu JH, Chen GH, Yang CM, Lu H, Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Hong RX, Jiang KK, Zhong YY, Zhang G, Tienchaiananda P, Oikawa M, Yuan ZY, Chen QJ
Breast Cancer: Targets and Therapy 2024, 16:223-231
Published Date: 12 April 2024
Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers
Dakroub R, Huard S, Hajj-Younes Y, Suresh S, Badran B, Fayyad-Kazan H, Dubois T
Breast Cancer: Targets and Therapy 2023, 15:785-799
Published Date: 6 November 2023
Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer
Tong L, Yu X, Wang S, Chen L, Wu Y
Breast Cancer: Targets and Therapy 2023, 15:647-658
Published Date: 24 August 2023
Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration
Tremmel E, Hofmann S, Kuhn C, Heidegger H, Heublein S, Hermelink K, Wuerstlein R, Harbeck N, Mayr D, Mahner S, Ditsch N, Jeschke U, Vattai A
Breast Cancer: Targets and Therapy 2019, 11:87-97
Published Date: 19 February 2019
Breast cancer prevention in older women: an algorithm to choose an optimal preventive agent
Ozdemir BZ, Goodin JB, Bodenner DL
Breast Cancer: Targets and Therapy 2019, 11:81-86
Published Date: 19 February 2019
The antiestrogenic effects of black cohosh on BRCA1 and steroid receptors in breast cancer cells
Crone M, Hallman K, Lloyd V, Szmyd M, Badamo B, Morse M, Dinda S
Breast Cancer: Targets and Therapy 2019, 11:99-110
Published Date: 19 February 2019
Breast cancer risk in a rapidly aging population: advances and approaches to study the aging tissue microenvironment
Greco SJ
Breast Cancer: Targets and Therapy 2019, 11:111-113
Published Date: 19 February 2019
Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
Ayoub NM, Al-Shami KM, Yaghan RJ
Breast Cancer: Targets and Therapy 2019, 11:53-69
Published Date: 17 January 2019